Vaxcyte (PCVX) Capital Expenditures (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Capital Expenditures data on file, last reported at $2.1 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 61.15% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 80.96% decrease from a year earlier, with the FY2025 full-year figure at $7.5 million, down 66.39% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.1 million, up from $2.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for PCVX reached as high as $15.6 million in Q4 2023 and fell as low as -$4.6 million in Q4 2022.
• Historically, Capital Expenditures has averaged $2.8 million across 5 years, with a median of $2.0 million in 2025.
• On a YoY basis, Capital Expenditures climbed as much as 744.73% in 2023 and fell as far as 542.35% in 2023.
• Year by year, Capital Expenditures stood at -$4.6 million in 2022, then surged by 440.43% to $15.6 million in 2023, then slumped by 74.27% to $4.0 million in 2024, then slumped by 51.01% to $2.0 million in 2025, then climbed by 6.95% to $2.1 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.1 million in Q1 2026, $2.0 million in Q4 2025, and -$1.7 million in Q3 2025.